Milestones | Phase III clinical enrollment of MAXVAX recombinant herpes zoster vaccine (CHO cells)

On July 13th, the Phase III clinical trial of the recombinant herpes zoster vaccine (CHO cells) of Chengdu MAXVAX Biotechnology Co., Ltd. (referred to as "MAXVAX Biotechnology") completed with the first subject enrolled in Liangyuan District, Shangqiu City, Henan Province, marking the smooth start of the Phase III clinical trial of MAXVAX Biotechnology's recombinant herpes zoster vaccine. This vaccine product adopts the recombinant protein technology route and is equipped with the independently developed new adjuvant system MA105. It is the first compound adjuvant system innovative vaccine in China that has entered phase III clinical trials and has independent intellectual property rights. The results of Phase I and II clinical trials show that the vaccine has good safety, tolerability, and immunogenicity. Phase III clinical trials will further verify the safety, immunogenicity, and protective efficacy of the vaccine in a large sample population, providing key data for product marketing applications.

Regarding the Herpes zoster vaccine

Herpes zoster is a viral infection caused by reactivation of the varicella zoster virus (the virus that causes chickenpox), resulting in a painful rash. It is commonly known as "snake wrap around the waist" and is most common in people over 50 years old. Vaccination against herpes zoster is the only way to prevent herpes zoster and postherpetic neuralgia.

Compared with the attenuated live herpes zoster vaccine no longer used in the United States, the recombinant herpes zoster vaccine using a new adjuvant system can activate stronger cellular immunity, improve the immune efficacy of the vaccine in elderly and immunocompromised populations, and provide better and longer lasting protection to the vaccinated population.

The recombinant herpes zoster vaccine (CHO cells) independently developed by MAXVAX Biotechnology is the first domestically produced herpes zoster vaccine with a new adjuvant system with independent intellectual property rights. It has now entered Phase III clinical trials. By developing adjuvant molecules and systems with independent intellectual property rights, MAXVAX Biotechnology is expected to enter the first tier of the global biopharmaceutical industry, providing safer and more effective prevention options for patients at home and abroad.